Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › TRIUMPH-1-OSA / TRIUMPH-2-OSA

TRIUMPH-1-OSA / TRIUMPH-2-OSA

Retatrutide · Obstructive sleep apnoea + obesity (with or without T2D)

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Retatrutide
Population
Obstructive sleep apnoea + obesity (with or without T2D)
Participants
691
Duration
80 weeks

Outcomes in the indication

TRIUMPH-1-OSA / TRIUMPH-2-OSA Retatrutide · Obstructive sleep apnoea + obesity (with or without T2D) · 80 weeks · n = 691 verified

AHI −24.4 (9 mg) and −21.9 (12 mg) events/h vs placebo without T2D; −14.4 and −15.1 with T2D (hybrid estimand, primary). Sub-studies nested in TRIUMPH-1 and TRIUMPH-2.

MeasureDrugControlDifference (95 % CI)Status
Apnea-hypopnea index, change from baseline (hybrid estimand) TRIUMPH-1-OSA, no T2D · 4 mg
week 80
−22.9−9.9−13.0 (−23.0 to −3.0) events/hverified
Apnea-hypopnea index, change from baseline (hybrid estimand) TRIUMPH-1-OSA, no T2D · 9 mg
week 80
−34.3−9.9−24.4 (−34.1 to −14.7) events/hverified
Apnea-hypopnea index, change from baseline (hybrid estimand) TRIUMPH-1-OSA, no T2D · 12 mg
week 80
−31.7−9.9−21.9 (−32.2 to −11.5) events/hverified
Apnea-hypopnea index, change from baseline (hybrid estimand) TRIUMPH-2-OSA, T2D · 4 mg
week 80
−19.2−10.3−8.9 (−15.9 to −2.0) events/hverified
Apnea-hypopnea index, change from baseline (hybrid estimand) TRIUMPH-2-OSA, T2D · 9 mg
week 80
−24.7−10.3−14.4 (−21.6 to −7.2) events/hverified
Apnea-hypopnea index, change from baseline (hybrid estimand) TRIUMPH-2-OSA, T2D · 12 mg
week 80
−25.4−10.3−15.1 (−22.5 to −7.7) events/hverified
Verbatim quotes (6)
  • Apnea-hypopnea index, change from baseline (hybrid estimand)
    −22.9 (−29.7 to −16.0)
  • Apnea-hypopnea index, change from baseline (hybrid estimand)
    −34.3 (−40.8 to −27.7)
  • Apnea-hypopnea index, change from baseline (hybrid estimand)
    −31.7 (−38.2 to −25.2)
  • Apnea-hypopnea index, change from baseline (hybrid estimand)
    −19.2 (−23.7 to −14.7)
  • Apnea-hypopnea index, change from baseline (hybrid estimand)
    −24.7 (−29.9 to −19.5)
  • Apnea-hypopnea index, change from baseline (hybrid estimand)
    −25.4 (−30.6 to −20.1)

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: TRIUMPH-1-OSA / TRIUMPH-2-OSA. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/triumph-1-osa-triumph-2-osa/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.